Allogene Therapeutics Inc (ALLO)
2.49
+0.03
(+1.22%)
USD |
NASDAQ |
May 31, 16:00
2.50
+0.01
(+0.40%)
After-Hours: 20:00
Allogene Therapeutics Enterprise Value: 135.01M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 135.01M |
| May 30, 2024 | 128.75M |
| May 29, 2024 | 101.61M |
| May 28, 2024 | 122.49M |
| May 24, 2024 | 141.28M |
| May 23, 2024 | 145.45M |
| May 22, 2024 | 170.51M |
| May 21, 2024 | 176.77M |
| May 20, 2024 | 155.89M |
| May 17, 2024 | 193.47M |
| May 16, 2024 | 243.58M |
| May 15, 2024 | 124.28M |
| May 14, 2024 | 120.87M |
| May 13, 2024 | 110.61M |
| May 10, 2024 | 86.70M |
| May 09, 2024 | 103.78M |
| May 08, 2024 | 86.34M |
| May 07, 2024 | 111.94M |
| May 06, 2024 | 129.02M |
| May 03, 2024 | 139.26M |
| May 02, 2024 | 122.19M |
| May 01, 2024 | 113.65M |
| April 30, 2024 | 86.34M |
| April 29, 2024 | 99.99M |
| April 26, 2024 | 108.53M |
| Date | Value |
|---|---|
| April 25, 2024 | 102.55M |
| April 24, 2024 | 134.14M |
| April 23, 2024 | 190.48M |
| April 22, 2024 | 195.60M |
| April 19, 2024 | 207.55M |
| April 18, 2024 | 205.84M |
| April 17, 2024 | 214.38M |
| April 16, 2024 | 211.73M |
| April 15, 2024 | 220.25M |
| April 12, 2024 | 262.86M |
| April 11, 2024 | 295.25M |
| April 10, 2024 | 308.88M |
| April 09, 2024 | 315.70M |
| April 08, 2024 | 293.54M |
| April 05, 2024 | 290.13M |
| April 04, 2024 | 305.47M |
| April 03, 2024 | 312.29M |
| April 02, 2024 | 308.88M |
| April 01, 2024 | 361.72M |
| March 31, 2024 | 377.06M |
| March 28, 2024 | 307.14M |
| March 27, 2024 | 305.45M |
| March 26, 2024 | 263.18M |
| March 25, 2024 | 276.71M |
| March 22, 2024 | 271.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-81.83M
Minimum
Nov 29 2023
6.280B
Maximum
May 22 2020
1.950B
Average
1.798B
Median
Oct 26 2021
Enterprise Value Benchmarks
| ANI Pharmaceuticals Inc | 1.432B |
| Vaxart Inc | 108.86M |
| Agenus Inc | 301.30M |
| BioCryst Pharmaceuticals Inc | 1.812B |
| Stereotaxis Inc | 147.33M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -65.00M |
| Revenue (Quarterly) | 0.022M |
| Total Expenses (Quarterly) | 69.53M |
| EPS Diluted (Quarterly) | -0.38 |
| Profit Margin (Quarterly) | -295.5K% |
| Earnings Yield | -73.09% |
| Normalized Earnings Yield | -73.09 |